Equities research analysts expect MOTIF BIO PLC/S (NASDAQ:MTFB) to post earnings per share of ($0.61) for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for MOTIF BIO PLC/S’s earnings. The lowest EPS estimate is ($0.76) and the highest is ($0.45). The business is scheduled to announce its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that MOTIF BIO PLC/S will report full-year earnings of ($2.16) per share for the current fiscal year, with EPS estimates ranging from ($3.01) to ($1.06). For the next year, analysts expect that the company will post earnings of ($1.95) per share, with EPS estimates ranging from ($2.87) to ($0.10). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow MOTIF BIO PLC/S.
A number of equities research analysts have recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price target on shares of MOTIF BIO PLC/S in a research report on Monday, June 11th. ValuEngine raised MOTIF BIO PLC/S from a “hold” rating to a “buy” rating in a research report on Tuesday, September 4th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $19.50.
MOTIF BIO PLC/S Company Profile
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.
Featured Article: What are the most popular ETFs
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MOTIF BIO PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MOTIF BIO PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.